Gastrointestinal Therapeutics and Diagnostics Market to Grow by 2031

New York, US – October 08, 2025 – The Insight Partners has published its latest market report titled “Gastrointestinal Therapeutics and Diagnostics Market Share, Size, Trends, and Forecast by 2031,” projecting substantial growth in the global market over the coming years. The report offers comprehensive insights into the current market landscape, key growth drivers, emerging trends, major challenges, and potential opportunities. It aims to inform stakeholders about the evolving dynamics of the industry, highlighting significant innovations and strategic developments expected through 2031.

Key Growth Drivers

1. Expansion of Therapeutic Options in GI Care:

A growing pipeline of innovative therapies, including biologics and novel drugs targeting gut microbiota and inflammatory gastrointestinal conditions, is propelling market development. Emphasis on personalized medicine, immunotherapy, and gene-based treatment approaches is enhancing therapeutic outcomes while reducing side effects, especially for chronic GI diseases.

2. Preference for Minimally Invasive Procedures:

There is a growing inclination among patients and healthcare providers toward less invasive diagnostic and therapeutic techniques, such as capsule endoscopy and advanced endoscopic procedures. These methods offer quicker recovery, lower procedural risks, and improved patient outcomes, thereby contributing significantly to market growth.

3. Increased Healthcare Spending and Infrastructure Enhancements:

Rising healthcare budgets and the expansion of medical infrastructure—particularly across emerging economies—are facilitating greater access to GI diagnostics and treatments. Countries in the Asia-Pacific region are witnessing a surge in investment in advanced diagnostic tools and healthcare facilities, leading to improved reach and patient care.

4. Technological Innovation in Diagnostics:

The market is benefiting immensely from the rapid adoption of advanced diagnostic technologies, including molecular diagnostics, AI-driven imaging, and smart capsule endoscopy. These innovations are making diagnostics more efficient, less invasive, and highly accurate, thereby encouraging broader implementation in clinical practice.

5. Heightened Public Awareness and Screening Initiatives:

Public health campaigns and government-sponsored screening programs have boosted early detection and intervention rates for GI disorders. These initiatives are fostering a culture of preventative care, significantly increasing the demand for both diagnostic and therapeutic solutions.

6. Aging Population and Related Health Needs:

The global rise in the elderly population correlates with a higher incidence of gastrointestinal disorders. Older individuals are more susceptible to conditions such as acid reflux, constipation, and GI cancers, leading to increased demand for diagnostic services, medications, and minimally invasive treatment solutions tailored to this demographic.

Get Sample Report: https://www.theinsightpartners.com/sample/TIPRE00020037/

Recent Industry Developments and Strategic Collaborations

Leading market participants are shaping the trajectory of the gastrointestinal therapeutics and diagnostics space through research, innovation, and acquisitions:

• AstraZeneca, on July 28, 2025, announced that its supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) was accepted for Priority Review by the US FDA. The drug is intended for use in patients with resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers (Stages II, III, IVA).
• On January 13, 2025, GSK plc entered into an acquisition agreement with IDRx, Inc., a clinical-stage biotech firm focused on targeted therapeutics for Gastrointestinal Stromal Tumors (GIST). The deal, valued at $1 billion upfront with an additional $150 million in milestone payments, includes the promising candidate IDRX-42, a selective KIT TKI for first- and second-line GIST treatment.

Leading Market Players

Several global pharmaceutical and biotech firms are central to the advancement of the gastrointestinal therapeutics and diagnostics market. Key players include:

• Abbott Laboratories
• AstraZeneca
• Eisai Co., Ltd.
• Johnson & Johnson
• Salix Pharmaceuticals
• Takeda Pharmaceuticals Company
• Bayer AG
• GlaxoSmithKline (GSK)
• Valeant Pharmaceuticals
• AbbVie, Inc.

These companies are investing heavily in R&D, forming strategic partnerships, and expanding their product pipelines to maintain competitiveness and meet evolving patient needs.

Future Market Outlook

The gastrointestinal therapeutics and diagnostics market is on track for sustained and significant growth through 2031. Continued advancements in precision medicine, growing adoption of minimally invasive technologies, and global improvements in healthcare infrastructure will drive the industry forward. Moreover, the rising prevalence of GI disorders and increased public health awareness are expected to further accelerate demand for innovative diagnostic and therapeutic solutions. Emerging markets, in particular, will play a vital role in expanding access and enhancing the global footprint of GI care.

Market Overview from The Insight Partners

According to The Insight Partners, the sector is experiencing rapid growth fueled by changing consumer needs, technological progress, and increased awareness of the benefits offered by modern GI diagnostics and treatments. In response, companies are expanding their portfolios, leveraging data-driven insights, and aligning with emerging trends to capitalize on market opportunities.

Access full Report Description, TOC, Table of Figure, Chart, etc. at https://www.theinsightpartners.com/buy/TIPRE00020037/

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.

Contact Us:

• If you have any queries about this report or if you would like further information, please get in touch with us:
• Contact Person: Ankit Mathur
• E-mail: ankit.mathur@theinsightpartners.com
• Phone: +1-646-491-9876
• Also Available in : Korean | German | Japanese | French | Arabic | Chinese | Italian | Spanish